A dose substitution of anthracycline intensity with dose-dense rituximab in children and adolescents with good-risk mature B-cell lymphoma-Reference-Cited by-同舟云学术

A dose substitution of anthracycline intensity with dose-dense rituximab in children and adolescents with good-risk mature B-cell lymphoma

Published:2021-05-03 Issue:10 Volume:35 Page:2994-2997
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Goldman Stan,Barth Matthew,Shiramizu Bruce,Shi Qiuhu,Hochberg Jessica,Klejmont Liana,Harrison Lauren,Basso Jackie,Chu Yaya,Islam Humayun,Gerard Perry,Agsalda-Garcia Melissa,Shieh Tiffany,Oesterheld Javier,Heym Kenneth,Kirov Ivan,Drachtman Richard,Harker-Murray Paul,Perkins Sherrie,Miles Rodney R.,Cairo Mitchell^ORCID

Funder

Pediatric Cancer Research Foundation

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

https://www.nature.com/articles/s41375-021-01256-8.pdf

Reference15 articles.

1. Cairo MS, Gerrard M, Sposto R, Auperin A, Pinkerton CR, Michon J, et al. Results of a randomized international study of high-risk central nervous system B non-Hodgkin lymphoma and B acute lymphoblastic leukemia in children and adolescents. Blood. 2007;109:2736–43.

2. Cairo MS, Sposto R, Gerrard M, Auperin A, Goldman SC, Harrison L, et al. Advanced stage, increased lactate dehydrogenase, and primary site, but not adolescent age (>/=15 years), are associated with an increased risk of treatment failure in children and adolescents with mature B-cell non-Hodgkin’s lymphoma: results of the FAB LMB 96 study. J Clin Oncol. 2012;30:387–93.

3. Patte C, Auperin A, Gerrard M, Michon J, Pinkerton R, Sposto R, et al. Results of the randomized international FAB/LMB96 trial for intermediate risk B-cell non-Hodgkin lymphoma in children and adolescents: it is possible to reduce treatment for the early responding patients. Blood. 2007;109:2773–80.